Introduction
============

Hypertension is a silent killer worldwide and an outcome of a convoluted interaction between genetic and environmental factors. The psychosocial stress caused by the fast-paced lifestyle of modern society, is an important risk factor for hypertension. Chronic stress leads to the generation of stress-induced hypertension (SIH) ([@B44]; [@B46]; [@B48]). Angiotensin II (Ang II) has important effects on the central modulation of cardiovascular activities. Ang II modulates sympathetic functions acting on a diverse range of receptors such as Ang II type 1 receptor (AT~1~R) and type 2 receptor (AT~2~R); the pressor effect of Ang II mainly results from the activation of AT~1~R ([@B33]).

Oxidative stress is caused by the imbalance between free radicals and antioxidants---an essential factor in hypertension. It has been indicated that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived reactive oxygen species (ROS), particularly superoxide anions (O~2~^.-^), are crucial intracellular messengers within Ang II signaling pathways ([@B18]; [@B36]). Ang II can upregulate mRNA and protein expression of NADPH oxidase subunits and augment production of ROS ([@B19]; [@B38]; [@B11]; [@B28]). In addition, ROS have been reported to participate in the modulation of sympathetic activities ([@B40]; [@B15]; [@B4]). NADPH oxidase-derived ROS act as essential intracellular messengers to activate downstream signaling molecules, including mitogen-activated protein kinase (MAPK) and transcriptional factors ([@B49]; [@B2]; [@B22]). It is reported that Ang II activates stress-activated protein kinase/Jun N-terminal kinase (SAPK/JNK), extracellular signal-regulated protein kinase 1/2 (ERK1/2), and p38MAPK, which are critical protein kinases for gene expression and cell growth ([@B29]). A previous study demonstrated that chronic Ang II infusion elevated NADPH oxidase subunit protein expression, ROS production, as well as p38MAPK activation, leading to hypertension in Sprague Dawley rats ([@B3]).

The rostral ventrolateral medulla (RVLM) has an important impact on the maintenance of sympathetic activities. It is widely accepted that the neurons in the RVLM provide downward impulses to the sympathetic preganglionic neurons in the intermediolateral column (IML) of the spinal cord, which projects the sympathetic nerves that dominate the heart and blood vessels ([@B45]). Our previous studies suggested that Ang II might activate glutamatergic neurons in the RVLM, resulting in the enhancement of blood pressure (BP) in Wistar and spontaneously hypertensive rats (SHR) ([@B20]). Moreover, AT1R, an angiotensin converting enzyme, mRNA and protein expression were significantly higher in the RVLM in stress-induced hypertensive rats (SIHR) compared with control rats ([@B12]). It has been shown that the elevated glutamatergic inputs to the RVLM contribute to increased BP and sympathetic activities in Goldblatt hypertension ([@B6]) and spontaneous hypertension ([@B47]). However, the cellular and molecular mechanisms underlying the central roles of Ang II in SIHR remain to be identified. Therefore, this study evaluated the hypothesis that Ang II mediates pressor response through AT1R-dependent NADPH oxidase derived-ROS-MAPK signaling pathways in the glutamatergic neurons of the RVLM of SIHR.

Materials and Methods {#s1}
=====================

Animals
-------

Adult male Sprague-Dawley rats (200--220 g) were randomly housed (5 per cage) at room temperature (22--27°C), on a 12/12 h light/dark schedule, and allowed free access to food and water. All experimental procedures were approved by the Animal Use and Care Committee of Shanghai Medical College, Fudan University and were performed in strict accordance with the guidelines of the National Institutes Health Guide for the Care and Use of Laboratory Animals.

Stress-Induced Hypertension Model
---------------------------------

Rats were randomly allocated into normotension (control) and stressed-induced hypertension (SIH) groups. The SIH model was created as described in our previous studies ([@B44]; [@B46]; [@B48]). Briefly, the rats of SIH group were placed in a cage with a grid floor and received 2-h random electric foot-shocks paired with interval noise stimulation, twice daily, for 15 days. The control rats received the same treatment excluding the stressful stimuli. Systolic blood pressure (SBP) in conscious rats was measured using the tail-cuff method at 2 h after stress and obtaining the average of three measurements. The criterion for hypertension in this experiment was determined as an SBP greater than 140 mmHg. After the 15-day stimulation period, the rats in the SIH group with an SBP less than 140 mmHg were removed from the follow-up experiments.

MABP Measurements
-----------------

After endotracheal intubation, the right carotid artery of each rat was cannulated to monitor BP continuously using a polygraph (Model SMUP-A, Department of Physiology and Pathophysiology, Shanghai Medical College of Fudan University, Shanghai, China). The heart rate (HR) was derived automatically from the BP phasic wave. During the experiment, the rectal temperature of rats was kept at 37 ± 0.5°C using a thermostat.

RVLM Microinjections
--------------------

Similar to the procedures reported previously ([@B46]), the rats were anesthetized with urethane/α-chloralose (urethane 0.75 g/kg; α-chloralose 70 mg/kg) intraperitoneally, and the bilaterally microinjection of test agents to the RVLM was performed with a micropipette (40--70 μm internal diameter) attached to a 0.5 μl microsyringe (Hamilton). The RVLM was located 0.8 mm from the first anterior branch of the hypoglossal nerve, 1.9 mm lateral, and 0.7 mm deeper toward the ventral surface. As a routine, a total volume of 50 nl was delivered to each side of the RVLM over 30 s to allow for complete diffusion of the test agents. The RVLM injection was verified by the presence of a transient pressor response (MABP greater than 15 mmHg) to an L-glutamate (2 nmol/50 nl) microinjection ([@B35]). Ang II, AT~1~R antagonist candesartan, and NADPH oxidase inhibitor apocynin, were purchased from Sigma-Aldrich (St. Louis, MO, United States). The SAPK inhibitor SP600125, ERK1/2 inhibitor U0126, and p38MAPK inhibitor SB203580 were obtained from Sigma-Aldrich (St. Louis, MO, United States). Artificial cerebrospinal fluid (aCSF) or 1% dimethyl sulphoxide (the solvent of SP600125, U0126, or SB203580) was used as a vehicle control. To avoid the confounding effects of drug interactions, each animal received only one pharmacological treatment. After the experiments, 50 nl of pontamine sky blue was injected through the micropipette to confirm the position (rostroventrolateral reticular nucleus, lateral paragigantocellular nucleus).

Fluorescence *in situ* Hybridization (FISH)
-------------------------------------------

The staining procedure was performed with an enhanced sensitive FISH detection kit (Servicebio, China). Six-micron cryosections were prepared ahead of time. We applied proteinase K (20 μg/ml) on the slice for 5 min to expose the nucleic acid and then washed the slides three times with 0.5M PBS. Following incubation with hybridization buffer at 37°C for 2 h, the slides were incubated with 50 μl of 8 ng/ul 5′,3′ double CY3-labeled RNA (VGLUT2 mRNA) detection probe and 5′,3′ double FAM-labeled RNA (AT~1~R mRNA) detection probe (TSINGKE, China) in the same buffer at 37°C overnight. After the samples were washed with different concentrations of SSC buffers. After three 5 min washes in PBS for the last time, the slides were detected under a Nikon Ni-U microscope (Nikon, Japan) and pictures were collected.

Intracerebroventricular (ICV) Infusion
--------------------------------------

Anesthetized rats were fixed in a stereotaxic apparatus (NeruoStar, United States). After the bregma was identified, an ICV cannula was implanted for the infusion of the inhibitors, as described previously ([@B10]). Once the anterior fontanel was identified, an ICV cannula was implanted into the right lateral cerebral ventricle 0.8 mm caudal to bregma, 1.5 mm lateral to the bregma, and 3.8 mm ventral to the zero level ([@B31]). The cannula was fixed to the cranium using dental acrylic and two stainless steel screws. The pump body was implanted subcutaneously. The rats underwent a 14-day ICV infusion of the SAPK/JNK inhibitor (SP600125), ERK1/2 inhibitor (U0126), p38MAPK inhibitor (SB203580) (0.5 μl/hr, 0.6 mmol/L), NADPH oxidase inhibitor APO (0.5 μl/hr, 0.45 mmol/L) ([@B13]), or aCSF via osmotic micro-pumps (Alzet, Cupertino, CA, United States). The position of the cannula in the lateral cerebral ventricle was confirmed by the staining of all four ventricles after injection of 5 μl of evans blue dye at the end of the experiments.

Intermediolateral Column (IML) Microdialysis
--------------------------------------------

After making an incision in the back to expose the T8 level of the thoracic segment and then removing the bone and meningeal membrane to expose the spinal cord surface, the microdialysis probe was inserted into the T8 spinal cord 0.45 mm lateral to the midline and 0.9 mm below the dorsal surface. The tip of the probe was in the IML. The probe was perfused (2 μl/min) with aCSF using a microdialysis pump (BASi, United States). Each dialysate sample was harvested for 10 min at a volume of 20 μl.

High-Performance Liquid Chromatography (HPLC)
---------------------------------------------

Amino acids of dialysate samples were separated using reverse-phase HPLC (Waters 1525, United States) and fluorescence detection (Waters 2475, United States) with a reverse-phase column (C18, ultrasphere octadecyl silane). The derivatized reagent consisted of 5 ml of absolute ethanol, 5 ml of 0.1 mol/L sodium tetraborate, 27 mg of orthophthaldialdehyde (Sigma-Aldrich, St. Louis, MO, United States), and 40 μl of β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, United States). The sample (20 μl) was mixed with the derivatized reagent (10 μl) for 90 s and then injected into the HPLC system. The mobile phase, which contained 63% 0.1 mol/L KH~2~PO4, 35% methanol, and 2% tetrahydrofuran, flowed through the system with a flow rate of 1.0 ml/min. The temperature of the column was 35°C. The excitation and emission wave lengths were 330 and 450 nm, respectively. For each sample, the analysis time was not more than 10 min.

Collection of Tissue Samples From the RVLM
------------------------------------------

On the 15th day, or after microinjections, rats were euthanized and their brains were removed and frozen on dry ice. Both sides of the ventrolateral medulla covering the RVLM (0.5--2.5 mm rostral to the obex and 1.4--2.4 mm lateral to the midline and medial to the spinal trigeminal tract) were dissected using a stainless steel micropunch (1 mm internal diameter) ([@B8]). Medullary tissues were stored at --80°C prior to protein analysis.

Western Blot Analysis
---------------------

The samples of brain tissues were homogenized in RIPA lysis buffer with protease or phosphatase inhibitor (Roche, Basel, Switzerland) and then centrifuged (12000 rpm, 15 min, 4°C) to obtain supernatants. The total protein concentration of the supernatants was determined using the BCA assay kit (Pierce). Samples were loaded and separated on the SDS--PAGE gel (40 μg per well). The protein was transferred to the PVDF membrane (Millipore, MA, United States), which was incubated overnight with primary antibodies at 4°C and then probed with the corresponding secondary antibody. The primary antibodies were as follows: rabbit anti-AT~1~R antibody (1:800 dilution, Abcam, MA, United States) ([@B9]; [@B41]), rabbit anti-SAPK/JNK antibody, mouse anti-phospho-SAPK/JNK antibody, mouse anti-ERK1/2 antibody, rabbit anti-phospho-ERK1/2 antibody, rabbit anti-p38MAPK antibody, rabbit anti-phospho-p38MAPK antibody and rabbit anti-β-tublin antibody (1:1000 dilution, Cell Signaling Technology, Danvers, MA, United States). The membranes were detected by an ECL-Plus detection kit (Tiangen, Beijing, China), and scanned using Image Quant LAS 4000 (GE Healthcare Life Sciences, CT, United States). The images were quantified using the ImageJ densitometry system.

Measurement of ROS in the RVLM
------------------------------

The lucigenin-enhanced chemiluminescence assay was adopted to detect the ROS production in the RVLM ([@B7]). RVLM was homogenized in PBS (20 mM, pH 7.4) containing EDTA (0.01 mM). The homogenate was centrifuged at 1200 × *g* for 10 min at 4°C and the supernatant was collected for ROS assay. Background chemiluminescence in a 2-ml buffer mixed with lucigenin (5 μmol/L) was detected for 5 min. Adding 100 μl supernatant, the chemiluminescence was detected for 30 min at room temperature. The production of ROS was determined and expressed as average light units per minute per milligram of protein.

Immunohistochemistry
--------------------

The procedure for immunohistochemistry was described previously ([@B32]). One section from every six serial sections was picked up, with a total of five sections in each animal. Tissue sections were deparaffinized, rehydrated by graded ethanol series, pre-incubated with 5% BSA for an hour, and then incubated with mouse anti-phospho-SAPK/JNK antibody (1:50 dilution, Cell Signaling Technology, Danvers, MA, United States), rabbit anti-phospho-ERK1/2 antibody (1:200 dilution, Cell Signaling Technology, Danvers, MA, United States), or rabbit anti-phospho-p38MAPK antibody (1:400 dilution, Cell Signaling Technology, Danvers, MA, United States) at 4°C overnight. The sections were washed three times with PBS and then incubated with corresponding secondary antibodies. The color reaction was carried out with HRP-linked polymer detection system.

Quantitative Real-Time PCR
--------------------------

The total RNA was extracted from lung tissues using TRIzol Reagent (Invitrogen Corporation, CA, United States). First-strand cDNA was synthesized and amplified from 0.5 μg of total RNA using the ReverTra Ace qPCR RT Kit (Toyobo, Tokyo, Japan). Then the mRNA levels of AT~1~R were measured by quantitative real-time PCR (iCyler iQ Real-time PCR Detection System, Bio-Rad Laboratories Inc., United States) using SYBR Green Real-time PCR Master Mix (Toyobo, Japan) in a total volume of 20 μL. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal standard to normalize the expression level of each mRNA. Primers were designed by Sangon Biotech (Shanghai, China). The target gene names and their primer sequences were shown as follows: forward primer 5′-CCCAAGTCCACACATCAAAG-3′, reverse primer 5′-GCAAGGCAGACTGTATGGAA-3′ for AT~1~R; and forward primer 5′-AAGGTGGTGAAGCAGGCGGC-3′, reverse primer 5′-GAGCAATGCCAGCCCCAGCA-3′ for GAPDH. The PCR amplification consisted of 40 cycles of denaturation (94°C, 15 s), annealing (60°C, 30 s) and extension (72°C, 30 s). All the samples were assayed in one essay in our study. The relative quantification of gene expression was analyzed from the measured threshold cycles (CT) by using the 2-ΔΔCt method in the experiment.

Statistical Analysis
--------------------

All of the data are presented as mean ± standard error (SE). Student's *t*-test, paired *t*-test, or analysis of variance (ANOVA) was performed as appropriate. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 16.0. A *P* \< 0.05 was considered statistically significant.

Results
=======

The Systolic Blood Pressure (SBP) and Heart Rate (HR) of the Stressed Rats Increase in a Time-Dependent Manner
--------------------------------------------------------------------------------------------------------------

Systolic blood pressure and HR of the stressed rats significantly increased from the 6th day compared with the control rats (^∗^*P* \< 0.05). SBP and HR of stressed rats was also significantly different from the 6th day compared with baseline (3rd day prior to stress) (^\#^*P* \< 0.05), and stayed stable at a high level around the 15th day (Figures [1A,B](#F1){ref-type="fig"}). However, there was no discernible difference in body weight between the SIH and control group (Figure [1C](#F1){ref-type="fig"}).

![The changes of systolic blood pressure (SBP) **(A)**, heart rate (HR) **(B)**, and body weight **(C)** in stress-induced hypertension (SIH) and control group. *n* = 10, *^∗^P* \< 0.05 vs. control (Student's *t*-test); ^\#^*P* \< 0.05 vs. baseline (paired *t*-test) (third day prior to stress).](fphys-09-01860-g001){#F1}

AT~1~R and VGLUT2 Co-localize in the RVLM and the Release of Glutamate Increases in the IML of SIHR
---------------------------------------------------------------------------------------------------

Figure [2A](#F2){ref-type="fig"} showed that AT~1~R and VGLUT2 co-localized in the RVLM of SIHR, suggesting that AT~1~R expressed in the glutamatergic neurons. To establish that the development of SIH is associated with the actions of glutamatergic neurons in the RVLM, we examined the concentration of amino acid neurotransmitters in the IML. We found the release of glutamate (Glu) neurotransmitter increased in SIHR (Figure [2C](#F2){ref-type="fig"}) than in the control rat (Figure [2B](#F2){ref-type="fig"}) (*n* = 8, *P* \< 0.05, Figure [2D](#F2){ref-type="fig"}). These data reveal that the activated glutamatergic neurons of the RVLM release more glutamate neurotransmitter to the IML of SIHR.

![Localization of AT~1~R and VGLUT2 in the rostral ventrolateral medulla (RVLM) of SIH rat **(A)** and chromatogram of amino acids in the IML in control **(B)** and SIH rats **(C)** the red (cy3), green (FAM) areas represented the staining of glutamatergic neurons and AT~1~R, respectively. Scale bars = 25 μm. The baseline release of glutamate increased in SIH rats compared with control rats **(D)**. *n* = 8, ^∗^*P* \< 0.05 vs. control (Student's *t*-test). Glu, glutamate; Gln, glutamine.](fphys-09-01860-g002){#F2}

Exogenous Ang II Activates SAPK/JNK, ERK1/2 and p38MAPK in the RVLM of SIHR
---------------------------------------------------------------------------

As Figure [3](#F3){ref-type="fig"} shows, SAPK/JNK, ERK1/2, and p38MAPK phosphorylation in the RVLM were much higher in SIHR than in control rats. RVLM microinjection of Ang II (50 pmol) increased SAPK/JNK, ERK1/2, and p38MAPK phosphorylation in SIHR at 15 min after application, and lasted at least 30 min; while total SAPK/JNK, ERK1/2, or p38MAPK levels were unchanged (Figures [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}).

![The protein levels of phosphorylation or total SAPK/JNK **(A)**, ERK1/2 **(B)**, and p38MAPK **(C)** in the RVLM in the SIH group 15 and 30 min after RVLM microinjection of Ang II (50 pmol). Densitometry values were determined as indicated. *n* = 4, ^∗^*P* \< 0.05 vs. control; ^\#^*P* \< 0.05 vs. SIH (one-way ANOVA with Tukey *post hoc* test).](fphys-09-01860-g003){#F3}

Antagonist of AT~1~R Decreases ROS Production and SAPK/JNK, ERK1/2, and p38MAPK Phosphorylation in the RVLM of SIHR
-------------------------------------------------------------------------------------------------------------------

The production of ROS was significantly higher in the RVLM of SIHR (Figure [4A](#F4){ref-type="fig"}). Furthermore, the enhancement of ROS production and SAPK/JNK, ERK1/2, and p38MAPK phosphorylation were discernibly blunted (Figures [4B,C](#F4){ref-type="fig"}) by administration of candesartan (2 nmol, an AT~1~R antagonist) to the RVLM, bilaterally. However, there was no discernible change elicited by microinjection of PD123319 (2 nmol, an AT~2~R antagonist) to the RVLM, bilaterally (data not shown). These findings implicate that stress elevates phosphorylation of SAPK/JNK, ERK1/2, and p38MAPK and activates MAPK pathway via AT~1~R.

![Effects of candesartan (CAN) on the production of Reactive oxygen species (ROS) and phosphorylation of SAPK/JNK, ERK1/2, and p38MAPK in the RVLM in SIH and control groups. The production of ROS in the RVLM detected at 20 min after microinjection of apocynin APO (2 nmol) or CAN (2 nmol) into the RVLM **(A)**; *n* = 6. The protein levels of phosphorylated SAPK/JNK, ERK1/2, and p38MAPK were detected 30 min after microinjection of CAN (2 nmol) into the RVLM, bilaterally **(B,C)**; *n* = 4. ^∗^*P* \< 0.05 vs. control + aCSF; ^\#^*P* \< 0.05 vs. SIH + aCSF (one-way ANOVA with Tukey *post hoc* test).](fphys-09-01860-g004){#F4}

NADPH Oxidase Inhibitor Inhibits the Activation of MAPK in the RVLM of SIHR
---------------------------------------------------------------------------

Bilateral administration of NADPH oxidase inhibitor APO (2 nmol) significantly inhibits SAPK/JNK, ERK1/2, or p38MAPK activation in the RVLM of SIHR (Figures [5A](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}). These findings suggest that NADPH oxidase-derived ROS might be an upstream signaling molecule within the MAPK pathway.

![Effects of APO on MAPK activation in the RVLM in the SIH and control group. Immunohistochemistry for p-SAPK/JNK **(A)**, p-ERK1/2 **(B)**, or p-p38MAPK **(C)** in control and SIH groups treated with or without APO **(D)**. Scale bars = 50 μm in a1, b1, c1; 25 μm in a2, b2, c2. *n* = 4, ^∗^*P* \< 0.05 vs. control + aCSF; ^\#^*P* \< 0.05 vs. SIH + aCSF (one-way ANOVA with Tukey *post hoc* test).](fphys-09-01860-g005){#F5}

Inhibitor of SAPK, but Not ERK1/2 or p38MAPK, Inhibits AT~1~R Expression in the RVLM of SIHR
--------------------------------------------------------------------------------------------

Both RT-PCR and Western blot studies showed that APO or SAPK inhibitor SP600125 led to a profound decrease in AT~1~R mRNA and protein expression in the RVLM of SIHR, whereas ERK1/2 inhibitor U0126 or p38MAPK inhibitor SB203580 did not demonstrate a significant effect in AT~1~R mRNA and protein expression in the RVLM of SIHR (Figures [6A,B](#F6){ref-type="fig"}).

![Effects of the inhibitors of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, SAPK/JNK, ERK1/2, and p38MAPK on AT~1~R expression in the RVLM and Mean arterial blood pressure (MABP) in rats with SIH. The mRNA levels of AT~1~R in the RVLM (*n* = 4) **(A)**, and change in MABP (*n* = 6) **(C)** in response to microinjection of APO (2 nmol), SP600125 (500 nmol), U0126 (500 nmol), or SB203580 (500 nmol) into the RVLM of rats with SIH. Representative gels or densitometric analysis of AT~1~R protein in the RVLM (*n* = 5) **(B)**, and change in MABP (*n* = 6) **(D)** of SIH group after intracerebroventricular infusion (ICV) of aCSF, APO (0.45 mol/L), SP600125 (0.6 mol/L), U0126 (0.6 mol/L), or SB203580 (0.6 mol/L) for 14 days in stress-induced hypertensive rats (SIHR). ^∗^*P* \< 0.05 vs. control + aCSF; ^\#^*P* \< 0.05 vs. SIH + aCSF (one-way ANOVA with Tukey *post hoc* test, **A,B,D**; Student's *t*-test, **C**).](fphys-09-01860-g006){#F6}

Inhibitors of NADPH Oxidase and SAPK Decreased MABP of SIHR
-----------------------------------------------------------

Bilateral microinjection of the APO (2 nmol) or the SAPK inhibitor SP600125 (500 nmol) into the RVLM decreased MABP of SIHR. However, administration of the ERK1/2 inhibitor U0126 (500 nmol) or p38MAPK inhibitor SB203580 (500 nmol) into the RVLM did not obviously change the MABP of SIHR (Figure [6C](#F6){ref-type="fig"}). There was no obvious change in the HR of SIHR. In addition, microinjection of SP600125, U0126, or SB203580 into regions adjacent to the RVLM had no discernible change in the MABP or HR of SIHR. ICV infusion of the APO (0.45 mmol/L) or SP600125 (0.6 mmol/L) for 14 days decreased MABP in the SIHR, whereas U0126 (0.6 mmol/L) or SB203580 (0.6 mmol/L) did not obviously change the MABP of SIHR (Figure [6D](#F6){ref-type="fig"}).

Discussion
==========

Hypertension is a major risk factor for cardiovascular and cerebrovascular diseases, which affects over one billion individuals worldwide ([@B43]; [@B27]). SIH caused by chronic and excessive stress, is inflicted on an increasing number of people, including young adults. Therefore, it is necessary to understand the mechanism underlying SIH. The SIHR model is established by electric foot-shocks combined with interval noises ([@B44]; [@B46]; [@B48]). The present experiment revealed that this chronic stress in rats led to an increase in BP, implying the successful establishment of an SIHR model.

In the current study, we examined the roles of AT~1~ R on cardiovascular modulation and the effects of NADPH oxidase-derived ROS-MAPK signaling in the glutamatergic neurons of the RVLM in SIHR. The primary findings of the present study are: (1) AT~1~R expressed in the glutamatergic neurons of the RVLM of SIHR and the glutamate in the IML of the spinal cord is higher in SIHR than that in control rats. (2) Exogenous Ang II activates SAPK/JNK, ERK1/2, and p38MAPK in the RVLM of SIHR. AT~1~R antagonist and NADPH oxidase inhibitor reduce the enhanced production of ROS and the activation of SAPK/JNK, ERK1/2, and p38MAPK in the RVLM of SIHR. (3) Injection of the SAPK/JNK inhibitor, but not the p38MAPK or the ERK1/2 inhibitor, into the RVLM significantly decreases expression of AT~1~R mRNA and MABP in SIHR. ICV infusion of the SAPK/JNK inhibitor for 14 days, but not the p38MAPK or the ERK1/2 inhibitor, significantly decreases the expression of AT~1~R protein and MABP in SIHR.

First, we identified that AT~1~R in glutamatergic neurons played a crucial role in the pathogenesis of SIH. Fluorescence *in situ* hybridization (FISH) analysis showed that the AT~1~R and VGLUT2 co-localized in the RVLM of SIHR, which indicated that the activity that Ang II bands to AT~1~R in the RVLM, is connected to the glutamatergic neurons. A majority of the glutamatergic neurons were co-localized with AT~1~R in the RVLM of Wistar rats and SHR ([@B20]). In hypertensive Dahl salt-sensitive rats, the elevated BP response to AT~1~R activation in the hypothalamic paraventricular nucleus (PVN) has been shown to be partly regulated by increased glutamate receptor activation ([@B14]). Ang II infusion increases co-localization of gp91^phox^-containing NADPH oxidase and glutamate N-methyl-D-aspartate receptor (NMDAR) NR~1~ subunit in the dendrites of PVN neurons, and augments baseline and NMDAR-induced production of ROS in PVN cells and spinally projecting PVN neurons ([@B39]). Our findings provide evidence that AT~1~R expressed in the glutamatergic neurons of the RVLM in SIHR, indicating that Ang II might evoke the activation of glutamatergic neurons via AT~1~R in the RVLM of SIHR. Furthermore, HPLC analysis showed that the glutamate was increased in the IML of spinal cord. It has been shown that projections from the RVLM to the IML of spinal cord dominate preganglionic neurons resulting in the elevated BP and HR ([@B17]; [@B30]). Our previous studies determined that Ang II-induced glutamate release in the spinal cord might arise from the AT~1~R-containing glutamatergic spinally projecting neurons in the RVLM of SHR ([@B20]). Our present findings implicate that, in SIHR, the glutamatergic neurons of the RVLM are activated, which are associated with the binding of Ang II to AT~1~R, and the further release of more glutamate neurotransmitter into the IML through projection fibers. The vesicular glutamate transporters (VGLUTs), capable of specifically packaging glutamate into presynaptic vesicles and promoting glutamate release ([@B24]), comprise three members, wherein VGLUT1 and VGLUT2 are considered as specific markers of canonical glutamatergic neurons. Additionally, VGLUT2-immunoreactivities were widely observed in the lower brainstem ([@B37]).

Chronic infusion of Ang II into the brain of normal rabbits resulted in sympathoexcitation and increased oxidative stress, as well as an upregulation of several of the protein subunits of NADPH oxidase, which have shown to be inhibited by losartan ([@B16]). In a study performed in rabbits with chronic heart failure, central administration of losartan, superoxide dismutase mimetic tempol, or NADPH oxidase inhibitor APO, reduced sympathetic nerve activity and oxidative stress ([@B15]). What is more, other models demonstrated similar findings, such as cardiac diastolic dysfunction ([@B23]) and nitric oxide inhibition induced-hypertension ([@B34]). In our experiments, ICV infusion for 14 days or RVLM microinjection of NADPH oxidase inhibitor APO obviously decreased MABP in the SIHR. These results implicate that AT~1~R and oxidative stress elicited by NADPH oxidase have an important effect on the regulation of sympathetic activities.

Secondly, we observed that the MAPK pathway was activated in SIHR and, specifically, that Ang II activated the MAPK pathway via AT~1~R. The current data show that SAPK/JNK, ERK1/2, and p38MAPK phosphorylation in the RVLM were significantly higher in SIHR than in control rats. Additionally, exogenous Ang II application to the RVLM causes this increase in SAPK/JNK, ERK1/2, and p38MAPK phosphorylation in SIHR. The enhanced activation of MAPKs has been observed in pulmonary arterial hypertension and spontaneous hypertension ([@B5]; [@B1]). Importantly, we found that the activation of SAPK/JNK, ERK1/2, and p38MAPK in the RVLM was significantly inhibited by bilateral microinjection of AT~1~R antagonist candesartan, which can cross the blood-brain barrier easily.

Our findings might not be consistent with previous studies noting that in normal rats, Ang II elicited ERK1/2 and p38MAPK phosphorylation, whereas SAPK/JNK was not activated in normal rats ([@B7]). The difference between the current study and these previous results is that SAPK/JNK, ERK1/2, and p38MAPK phosphorylation induced by Ang II administration may be related to the specialty of the current SIH model. Chronic and excessive stress can activate not only ERK1/2 and p38MAPK, but also the stress related proteins SAPK/JNK, to regulate sympathetic activity further.

Thirdly, we demonstrated that NADPH oxidase-derived ROS is the upstream messenger that mediated SAPK/JNK, ERK1/2, and p38MAPK activation induced by Ang II binding to AT~1~R in the RVLM of SIHR. We identified that the production of ROS enhanced in SIHR compared with control rats. Microinjections of AT~1~R antagonist candesartan and NADPH oxidase inhibitor APO into the RVLM partially inhibited ROS production and SAPK/JNK, ERK1/2, and p38MAPK phosphorylation in SIHR. APO also inhibited the elevation of MABP in SIHR. A previous study suggested that NADPH oxidase-derived ROS mediated the Ang II-evoked pressor effect via p38MAPK activation in the RVLM of normal rats ([@B7]). The present study suggests that in the RVLM of SIHR, NADPH oxidase-derived ROS has a crucial effect on SAPK/JNK, ERK1/2, and p38MAPK activation elicited by endogenous Ang II.

Finally, we noted that SAPK/JNK activation in the RVLM had important effects on AT~1~R expression and the modulation of pressor response. The enhancement of AT~1~R mRNA expression and MABP in SIHR were attenuated by the bilateral microinjection of SAPK/JNK inhibitor SP600125, but not ERK1/2 inhibitor U0126, or p38MAPK inhibitor SB203580. Besides, ICV infusion of the SAPK/JNK inhibitor, not ERK1/2, or p38MAPK inhibitor for 14 days decreased AT~1~R protein expression and MABP in the SIHR, Our previous study demonstrated that endogenous Ang II production was increased in SIHR and AT~1~R expression in the RVLM was much higher in SIHR than in control rats ([@B12]). Hence, we suggested that SAPK/JNK played a major role in regulating the pressor effect.

The AT~1~R expression was enhanced in the RVLM of normal rabbits infused with Ang II and rabbits with heart failure ([@B16]; [@B25]). It has been reported that Ang II induces MAPK signaling to upregulate AT~1~R in PVN and contributes to AT~1~R-mediated sympathetic excitation in heart failure ([@B42]). Ang II activates diverse nuclear transcription factors, such as activator protein-1 (AP-1) ([@B21]), some of which participate in AT~1~R gene transcription. There was some evidence that Ang II promoted the upregulated transcription of AT~1~R by oxidant stress and AP-1 activation in the intact brain of rabbits and cultured neuronal cells ([@B26]). The enhancement of AP-1 upregulated AT~1~R expression in the RVLM of rabbits with heart failure, which was activated by the SAPK/JNK pathway ([@B25]). Furthermore, Ang II-evoked ERK1/2 phosphorylation also functioned in central sympathetic activities via transcription regulation. For example, the PKCb/NADPH oxidase/ERK1/2/CREB/c-fos signaling cascade modulates the long-term pressor effect induced by Ang II in the RVLM of normal rats ([@B8]). Our present findings indicate that SAPK/JNK, but not ERK1/2 or p38MAPK, has a crucial effect on the modulation of pressor response and AT~1~R expression in the RVLM of SIHR. The findings reveal that Ang II upregulates its own receptors via positive feedback involving the AT~1~R-ROS- SAPK/JNK pathway (Figure [7](#F7){ref-type="fig"}).

![Schematic diagram showing the mechanism by which AT~1~R mediates pressor effect in the glutamatergic neurons of the RVLM of SIHR. Ang II triggers the activation of NADPH oxidase derived ROS-SAPK pathway via AT~1~R in the glutamatergic neurons of the RVLM of SIHR, then may activate activator protein (AP)-1 to evoke gene transcription and increase AT~1~R expression, which promotes the release of glutamate in the IML and eventually increases BP and HR.](fphys-09-01860-g007){#F7}

Overall, the present data show that AT~1~R localizes in the glutamatergic neurons of the RVLM of SIHR. This localization results in the release of glutamate into the IML of the spinal cord, leading to the pressor response in SIHR. Further, the NADPH oxidase-ROS-SAPK/JNK pathway has an essential impact on the actions of glutamatergic neurons and promotes the expression of AT~1~R in the RVLM of SIHR. Thus, this study reveals that Ang II modulates pressor effect through AT~1~R-dependent activation of SAPK/JNK by NADPH oxidase-derived ROS in the glutamatergic neurons of the RVLM in SIHR. One limitation of the present study is that we didn't examine the expression of AP-1 and the role of AP-1 in SIHR, although it has been reported that AP-1 activation might participate in the upregulation of AT~1~R in heart failure. This interesting possibility in SIHR will be investigated in our future study.
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aCSF

:   artificial cerebrospinal fluid

Ang II

:   angiotensin II

AP-1

:   activator protein-1

APO

:   apocynin

AT~1~R

:   angiotensin II type 1 receptors

BP

:   blood pressure

CAN

:   candesartan

FISH

:   fluorescence *in situ* hybridization

Glu

:   glutamate

HR

:   heart rate

ICV

:   intracerebroventricular

IML

:   intermediolateral column

MABP

:   mean arterial blood pressure

ROS

:   reactive oxygen species

RVLM

:   rostral ventrolateral medulla

SBP

:   systolic blood pressure

SHR

:   spontaneously hypertensive rats

SIH

:   stress-induced hypertension

SIHR

:   stress-induced hypertensive rats
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